Enecadin
Alternative Names: NS 7; ZK 228326Latest Information Update: 17 Aug 2009
At a glance
- Originator Nippon Shinyaku
- Class Neuroprotectants; Pyrimidines; Small molecules
- Mechanism of Action Calcium channel antagonists; Calpain inhibitors; Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Neurological disorders; Stroke
Most Recent Events
- 01 Feb 2006 Phase-II clinical trials in Stroke in Germany (unspecified route)
- 07 Oct 2004 Enecadin has been licensed to PAION worldwide except Japan
- 21 Jul 2003 Discontinued - Phase-II for Stroke in Europe (unspecified route)